formulated different populations need addressed not feasible test possible combination large clinical trials instead evaluating combinations cell culture accelerate vaccine development lower risk levy says researchers hope eventually test candidate vaccine adjuvant pairs elderly individuals globe sure finished product work wide range people possible adds groups including world working covid-19 vaccines cambridge Massachusetts biotech company moderna supported nih developed candidate genetic sequence virus tested patients moderna approach based protein making instructions called messenger rna mrna never employed approved vaccine covid-19 outbreak technology tested 1,000 healthy people effectively generated immune response diseases said tal zaks moderna chief medical officer article published